Abstract: The invention provides polynucleotide constructs for the regulation of gene expression by aptamer-based modulation of the accessibility of one or more polyadenylation signals and methods of using the constructs to regulate gene expression in response to the presence or absence of a ligand that binds the aptamer. The polynucleotide construct contains a riboswitch comprising an aptamer and an effector stem loop, wherein the effector stem loop comprises a polyadenylation signal sequence.

Abstract: The invention provides antibodies that specifically bind to PD-L1 and fusion molecules comprising PD-L1 binding proteins constructed with an IL 15 receptor-binding domain, nucleic acid molecules encoding the same, and therapeutic compositions thereof. The agents inhibit PD-L1-mediated immunosuppression and enhance cell and cytokine mediated immunity for the treatment of neoplastic and infectious diseases.

Abstract: The invention provides antibodies that specifically bind to PD-L1 and fusion molecules comprising PD-L1 binding proteins constructed with an IL 15 receptor-binding domain, nucleic acid molecules encoding the same, and therapeutic compositions thereof. The agents inhibit PD-L1-mediated immunosuppression and enhance cell and cytokine mediated immunity for the treatment of neoplastic and infectious diseases.

Abstract: The invention provides polynucleotide constructs for the regulation of gene expression by aptamer-based modulation of the accessibility of one or more polyadenylation signals and methods of using the constructs to regulate gene expression in response to the presence or absence of a ligand that binds the aptamer. The polynucleotide construct contains a riboswitch comprising an aptamer and an effector stem loop, wherein the effector stem loop comprises a polyadenylation signal sequence.

Abstract: The invention provides antibodies that specifically bind to PD-L1 and fusion molecules comprising PD-L1 binding proteins constructed with an IL15 receptor-binding domain, nucleic acid molecules encoding the same, and therapeutic compositions thereof. The agents inhibit PD-L1-mediated immunosuppression and enhance cell and cytokine mediated immunity for the treatment of neoplastic and infectious diseases.

Abstract: The invention provides antibodies that specifically bind to PD-L1 and fusion molecules comprising PD-L1 binding proteins constructed with an IL15 receptor-binding domain, nucleic acid molecules encoding the same, and therapeutic compositions thereof. The agents inhibit PD-L1-mediated immunosuppression and enhance cell and cytokine mediated immunity for the treatment of neoplastic and infectious diseases.

Abstract: The invention described herein provides human antibodies produced in non-human animals that specifically bind to Streptococcus pneumoniae capsular polysaccharide (PPS-3). The invention further provides methods for making the antibodies in a non-human animal and for expressing the antibodies in cells including hybridomas and recombinant host cell systems. Kits and pharmaceutical compositions comprising the antibodies are also provided in addition to methods of treating, inhibitng or preventing S. pneumoniae infection or conditions or disorders caused by such infection by administering to a patient the pharmaceutical compositions described herein.

Abstract: The invention described herein provides human antibodies produced in non-human animals that specifically bind to Streptococcus pneumoniae capsular polysaccharide (PPS-3). The invention further provides methods for making the antibodies in a non-human animal and for expressing the antibodies in cells including hybridomas and recombinant host cell systems. Kits and pharmaceutical compositions comprising the antibodies are also provided in addition to methods of treating, inhibitng or preventing S. pneumoniae infection or conditions or disorders caused by such infection by administering to a patient the pharmaceutical compositions described herein.

Abstract: The invention described herein provides human antibodies produced in non-human animals that specifically bind to Streptococcus pneumoniae capsular polysaccharide (PPS-3). The invention further provides methods for making the antibodies in a non-human animal and for expressing the antibodies in cells including hybridomas and recombinant host cell systems. Kits and pharmaceutical compositions comprising the antibodies are also provided in addition to methods of treating, inhibitng or preventing S. pneumoniae infection or conditions or disorders caused by such infection by administering to a patient the pharmaceutical compositions described herein.